Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
3 Dow Stocks That Are Crushing It in 2022: Are They Buys Now?
09:55am, Wednesday, 25'th May 2022 The Motley Fool
These are the kinds of stocks you'd expect to flourish in a dismal market.
3 Recession-Proof Stocks To Protect Your Portfolio From Fed-Induced Turmoil
09:38am, Wednesday, 25'th May 2022 Investing.com
We've Only Just Begun
09:17am, Wednesday, 25'th May 2022 Seeking Alpha
Today's stock bear market has only just begun. Elevate your investment strategy to find opportunities that remain abundant within the broader market. Read more.
These 7 Dividend-Paying Warren Buffett Stocks Are Almost Recession Proof
07:35am, Wednesday, 25'th May 2022
If any investor has stood the test of time, it is Warren Buffett. For years, the “Oracle of Omaha” has had a rock-star-like presence in the investing world.
3 Dow Stocks That Are Crushing It in 2022: Are They Buys Now?
05:55am, Wednesday, 25'th May 2022
These are the kinds of stocks you'd expect to flourish in a dismal market.
Seagen (SGEN) Posts Positive Data from New Study on Tukysa
02:58pm, Tuesday, 24'th May 2022 Zacks Investment Research
Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.
7 Blue-Chip Stocks With Dividends to Buy Before June
06:09am, Tuesday, 24'th May 2022
Blue-chip stocks with dividends pay investors to wait for a rally by the stock market and tend to be quite resilient. The post 7 Blue-Chip Stocks With Dividends to Buy Before June appeared first on In
Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use
02:14pm, Monday, 23'rd May 2022 Zacks Investment Research
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
4 Dow Stocks Billionaire Money Managers Bought Hand Over Fist in the First Quarter
09:06am, Monday, 23'rd May 2022 The Motley Fool
Successful fund managers are piling into these four time-tested companies.
‘I chose to take a gamble’: Husband-wife lab researchers admit taking Pfizer vaccine data to develop their own cancer treatment
11:28pm, Sunday, 22'nd May 2022 MarketWatch
The plot unraveled after Chenyan Wu was caught trying to sneak toxic chemicals into the U.S. from China to start a lab in San Diego.
2 Safe Stocks to Buy in a Bear Market
02:23pm, Saturday, 21'st May 2022 The Motley Fool
These two leading companies have survived market downturns before.
7 Quality Dividend Stocks to Buy on the Dip
11:00am, Saturday, 21'st May 2022
While the current market environment is full of uncertainty, these dividend stocks to buy offer a hedge against the rampant inflation rates. The post 7 Quality Dividend Stocks to Buy on the Dip appear
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
06:17pm, Friday, 20'th May 2022 Zacks Investment Research
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
01:25pm, Friday, 20'th May 2022 Zacks Investment Research
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
4 Large Drug Stocks to Watch as the Industry Recovers
01:32pm, Thursday, 19'th May 2022 Zacks Investment Research
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are wor
